Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
More treatment choices are coming for patients with rare gut tumors. The FDA has approved both Bravnetsa and Bexlutry — two new lutetium Lu 177 dotatate formulations — as equivalent alternatives to Lutathera for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bravnetsa is the first radiopharmaceutical approved via the ANDA pathway, while Bexlutry came through the 505(b)(2) route, together opening new regulatory doors for the field.
Patients with a rare but challenging cancer just got more options. The FDA has approved two new lutetium Lu 177 dotatate formulations — Bravnetsa™ (by Lantheus) and Bexlutry™ (by Curium) — for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors. Both are considered equivalent to the established reference product, Lutathera®.
The approvals came through different regulatory pathways: Bravnetsa via the FDA's Abbreviated New Drug Application (ANDA) pathway — making it the first radiopharmaceutical ever deemed bioequivalent and therapeutically equivalent to Lutathera — while Bexlutry was approved via the 505(b)(2) pathway, which allows use of existing evidence plus bridging data to demonstrate a similar biological and chemical profile. Both are supplied as single-dose vials delivering 7.4 GBq (200 mCi) of radioactivity.
Key Takeaways:
Why it matters: GEP-NETs are rare but growing in diagnosed prevalence, and access to effective targeted radiotherapy has historically been limited. These approvals not only expand treatment availability but also signal a new era of regulatory innovation for radiopharmaceuticals — potentially improving supply reliability and broadening patient access.
